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Abstract
To determine the potential of a non-invasive acoustic device (CADScor®System) to reclassify patients with intermediate 
pre-test probability (PTP) and clinically suspected stable coronary artery disease (CAD) into a low probability group thereby 
ruling out significant CAD. Audio recordings and clinical data from three studies were collected in a single database. In all 
studies, patients with a coronary CT angiography indicating CAD were referred to coronary angiography. Audio recordings 
of heart sounds were processed to construct a CAD-score. PTP was calculated using the updated Diamond-Forrester score 
and patients were classified according to the current ESC guidelines for stable CAD: low < 15%, intermediate 15–85% and 
high > 85% PTP. Intermediate PTP patients were re-classified to low probability if the CAD-score was ≤ 20. Of 2245 patients, 
212 (9.4%) had significant CAD confirmed by coronary angiography ( ≥ 50% diameter stenosis). The average CAD-score 
was higher in patients with significant CAD (38.4 ± 13.9) compared to the remaining patients (25.1 ± 13.8; p < 0.001). The 
reclassification increased the proportion of low PTP patients from 13.6% to 41.8%, reducing the proportion of intermediate 
PTP patients from 83.4% to 55.2%. Before reclassification 7 (3.1%) low PTP patients had CAD, whereas post-reclassification 
this number increased to 28 (4.0%) (p = 0.52). The net reclassification index was 0.209. Utilization of a low-cost acoustic 
device in patients with intermediate PTP could potentially reduce the number of patients referred for further testing, without a 
significant increase in the false negative rate, and thus improve the cost-effectiveness for patients with suspected stable CAD.
Keywords Stable coronary artery disease · Heart sounds · Non-invasive testing · Reclassification · Cost-effectiveness · 
Ultrasensitive phonocardiography
Introduction
For detection of stable coronary artery disease (CAD), 
patients undergo risk stratification, non-invasive and inva-
sive testing [1]. However, recent studies have demonstrated 
that as low as 6–10% of patients referred to non-invasive 
testing suffer from significant CAD [2–4]. A safe and low-
cost rule-out test reducing the number of patients with non-
obstructive CAD referred to non-invasive testing could 
therefore reduce costs and potential risk of complications.
One approach for a simple and efficient tool for rul-
ing out CAD is the automated analysis of heart sounds to 
identify abnormalities such as weak murmurs related to 
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post stenotic turbulent flow in the coronary arteries [5] and 
abnormal myocardial vibration patterns [6, 7]. The first 
report of CAD-related heart sounds originates from the 
late sixties [8]. Since then a wide range of signal process-
ing algorithms for detection of CAD have been proposed 
[7, 9–16]. Recently some of these methods have undergone 
clinical testing [2, 17–20]. One method is the automated 
stethoscope-like device (CADScor®System, Acarix A/S), 
which obtains heart sounds from the coronary circulation 
and myocardium during a 3 min recording period at the 4th 
left intercostal space. A CAD-score on a scale from 0 to 99 
is estimated immediately after the recording using an inte-
grated algorithm performing advanced analysis of the heart 
sounds in combination with age, gender and blood pressure 
information. A CAD-score ≤ 20 indicates low probability of 
CAD and a recent study demonstrated a negative predictive 
value of 96% in a low to intermediate probability popula-
tion [2], positioning the device as a potential early rule-out 
modality before more extensive testing.
In the current study we assessed the potential of the CAD-
score algorithm to reclassify patients suspected of stable 
CAD from intermediate to low likelihood of CAD, to illus-
trate the rule-out capacity of the CADScor®System.
Methods
Study population
Heart sound recordings and patient data from three clinical 
studies were combined in a database. In short, the Acous-
tic Data collection for Optimizing CAD-score Algorithm 
study (AdoptCAD, NCT01564628) included 255 subjects 
referred for either coronary CT angiography (CTA) or 
coronary angiography (CAG) [21]. Patients where CTA 
identified a stenosis were further referred to CAG. A total 
of 249 patients had a heart sound recording. In the Dan-
Risk 5-year follow-up study (BIO-CAC; NCT02913144), 
a heart sound recording was obtained in 661 asympto-
matic subjects undergoing coronary artery calcium scor-
ing (CACS) [22, 23]. Subjects with a CACS above 400 
were offered myocardial scintigraphy and subjects with a 
CAD-score (algorithm version 2) above 37 (n = 60) were 
offered CTA. Subjects with a positive CTA or myocardial 
scintigraphy test were offered CAG (n = 12). In the Dan-
NICAD study (NCT02264717), heart sound recordings 
were successfully obtained in 1563 of 1675 patients with 
low to intermediate pre-test probability (PTP) referred for 
CTA with suspicion of CAD [2, 24]. Patients with at least 
one obstructive stenosis identified at CTA were referred 
for CAG. All studies were conducted in accordance 
with the Declaration of Helsinki. Informed consent was 
obtained from all individual participants included in the 
studies. The local scientific ethics committees approved 
the research protocols.
The CAD‑score
A CAD-score was estimated using an offline version of the 
CAD-score algorithm version 3.1 as embedded in the cur-
rent CADScor®System. The CAD-score device obtains 
two recording: first 30 s of pre-test recording to validate the 
sound quality, next if the pre-test recording passes the algo-
rithm quality control, 150 s are recorded. The heart sound 
signal is obtained by ultrasensitive phonocardiography using 
a microphone attached at the 4th intercostal space just to 
the left of the sternum. The algorithm automatically seg-
ments the heart sounds into systolic and diastolic periods 
[25]. Then the sounds are filtered before eight acoustic fea-
tures that describe relevant properties of the heart sounds 
are extracted from the diastolic and systolic periods [2, 6, 
26, 27]. These features are combined into an acoustic score 
using a linear discriminant function. Using logistic regres-
sion, the acoustic score is combined with gender, age, and 
hypertension (systolic blood pressure ≥ 140 mmHg or cur-
rent treatment with antihypertensive medication) to generate 
the CAD-score. The CAD-score is scaled so that 90% of 
patients with CAD have a CAD-score > 20. Hence, a CAD-
score value > 20 is categorized as abnormal, for further 
details see the online supplementary in Winther et al. [2].
The current algorithm version 3.1 was developed and 
calibrated in a subset including 1201 patients from the cur-
rent database as described by Winther et al. [2]. Before final 
implementation of the algorithm in the device, model coef-
ficients for both the linear discriminant analyses and logistic 
regression and the scaling were fine-tuned in the complete 
database reported here.
Reclassification
A simple reclassification scheme was applied to reclas-
sify the probability of CAD in symptomatic patients with 
suspected CAD from the AdoptCAD and the Dan-NICAD 
study. PTP was calculated using the updated Diamond-
Forrester score [28] according to the ESC guidelines [1]: 
low < 15%, intermediate 15–85% and high PTP > 85%. 
Patients in the intermediate PTP group (15–85%) were 
reclassified using the CAD-score. Patients with an interme-
diate PTP and a CAD-score ≤ 20 were reclassified to low 
probability, while patients from the intermediate PTP with 
a CAD-score > 20 were kept as intermediate probability. 
Patients with low ( < 15%) or high ( > 85%) PTP were not 
reclassified.
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Diagnosis
The disease level was divided into three levels: non-CAD, 
mild-CAD and significant-CAD. Significant-CAD is defined 
as having a stenosis with at least 50% diameter reduction 
defined by CAG [29]. Non-CAD is defined as having a 
CACS at zero and no stenosis identified at CTA. Mild-CAD 
is having some degree of CAD either CACS higher than zero 
or having an insignificant stenosis ether by CTA or CAG. 
Since the diagnostic flow differs from study to study, specific 
supplementary rules are used in coding of the AdoptCAD 
and the BIO-CAC study (Supplementary Table 1).
Statistical analysis
Variables are expressed as mean ( ± standard deviation (SD) 
or total range). Categorical variables are reported as frequen-
cies (percentages). The unpaired Student t test and ANOVA 
test were used for comparison between continuous variables. 
The chi square test was used for comparison between cat-
egorical variables. Pearsons correlation was used to analyse 
correlations between variables. The area under the receiver-
operating characteristic (AUC) curve was calculated for con-
tinuous variables and in paired designs compared with the 
method described by DeLong et al. [30] and in unpaired 
cases with the method of Hanley et al. [31]. The CAD-score 
was divided as a binary variable with a cut point of 20 and 
the updated Diamond-Forrester score using a cut point of 
15 to calculate sensitivity, specificity, positive and negative 
predictive values (PPV and NPV), and positive and nega-
tive likelihood ratio (PLR and NLR). Performance values 
are presented with 95% confidence intervals. The post-test 
probability was calculated using pre-test odds and likeli-
hood ratios by Bayesian statistics. Statistical analyses were 
performed using Matlab R2017b (MathWorks, US).
Since the current CAD-score algorithm version 3.1 is 
finetuned in the complete database, the current results could 
be a result of overfitting of the linear discriminant analysis 
and logistic regression. To test for overfitting, we did a 50 
times repeated tenfold cross-validation test where both the 
linear discriminant analysis and the logistic regression were 
re-trained [32].
Results
In the pooled population, 2473 patients had at least one 
acoustic heart sound recording. A CAD-score with algo-
rithm version 3.1 could be calculated in 2334 (94%) of 
the patients, the remaining 139 were excluded from the 
current analyses. Reasons for not obtaining a CAD-score 
were arrhythmia (n = 27), algorithm related errors (n = 60), 
too much noise/too weak heart sounds (n = 34) or missing 
clinical information such as symptoms or hypertension 
status (n = 18). Finally, 89 (3.6%) patients were excluded 
since they could not be assigned a disease level according 
the diagnostic scheme. The remaining 2245 patients were 
included in the current analyses.
The mean age of the population was 58.3 ± 8.4 years and 
included 1185 (52.8%) females and 1060 (47.2%) males 
(Table 1). The mean PTP for significant CAD according to 
the updated Diamond-Forrester score was 36.4%. A total of 
370 (16.5%) patients had a PTP below 15%, 1824 (81.2%) 
a PTP between 15 and 85% and 51 (2.3%) had a PTP above 
85%. CACS was conducted in 2239 patients (99.7%), 1614 
patients (71.9%) underwent CTA and 455 (20.3%) under-
went CAG. In total 212 (9.4%) patients had significant-CAD 
documented by CAG, 44.2% had mild-CAD and 46.4% had 
non-CAD (Supplementary Table 2).
The CAD‑score
The average CAD-score in the pooled population was 
26.4 ± 14.3. The average CAD-score was significantly higher 
in significant-CAD patients 38.4 ± 13.9 versus 25.1 ± 13.8 
in the remaining patients (p < 0.001). The distribution of 
CAD-scores by disease level is shown in Fig. 1. There was a 
significant stepwise increase in the average CAD-score with 
increasing severity of disease level (Supplementary Table 3). 
In 300 patients, one additional recording was obtained after 
the first recording, the intra-patient correlation between the 
first and the second CAD-score was r = 0.973 (p < 0.0001).
Reclassification
Of 1673 patients referred for testing due to suspected CAD 
(patients from the AdoptCAD and the Dan-NICAD study), 
227 (13.6%) patients were classified as having a low likeli-
hood of CAD ( < 15%) according to the PTP estimated by the 
updated Diamond-Forrester score. Post CAD-score-test this 
number increased to 699 (41.8%), thus reducing the number 
of patients classified with intermediate likelihood from 1395 
(83.4%) to 923 (55.2%) (Fig. 2). Before testing 7 (3.1%) low 
PTP patients had significant-CAD, whereas post-reclassifi-
cation this number increased to 28 (4.0%) (p = 0.52). The net 
reclassification index was 0.209.
Diagnostic performance
When separating significant-CAD patients from other patients 
(non-CAD and mild-CAD) the AUC of the CAD-score was 
0.750 (0.710–0.789) (Fig. 3, Table 2). The sensitivity of a 
CAD-score > 20 was 88.7% (83.6–92.6%) and the specificity 
of a CAD-score ≤ 20 was 41.5% (39.4–43.7%). The NPV of 
a CAD-score ≤ 20 was 97.2% (95.9–98.2%) while the PPV of 
a CAD-score > 20 was 13.7% (11.9–15.6%). The NLR and 
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Table 1  Baseline characteristics of included studies
All AdoptCAD Dan-NICAD BIO-CAC 
N 2245 199 1474 572
Sex (female) 1185 (52.8%) 93 (46.7%) 771 (52.3%) 321 (56.1%)
Age 58.3 ± 8.4 [20–86] 61.9 ± 11.0 [20–86] 57.1 ± 8.8 [40–80] 60.1 ± 5.0 [54–66]
BMI 26.9 ± 4.2 27.0 ± 4.3 26.6 ± 4.2 27.5 ± 4.4
Hypertension 1313 (58.5%) 137 (68.8%) 878 (59.6%) 298 (52.1%)
Dyslipidemia 1706 (76%) 159 (79.9%) 1100 (74.6%) 447 (78.1%)
Smoking
  Never 1068 (47.6%) 71 (35.7%) 712 (48.3%) 285 (49.8%)
  Former 817 (36.4%) 86 (43.2%) 537 (36.4%) 194 (33.9%)
  Active 360 (16.0%) 42 (21.1%) 225 (15.3%) 93 (16.3%)
Diabetes 118 (5.3%) 19 (9.6%) 75 (5.1%) 24 (4.2%)
Family history of CAD
  Yes 680 (30.3%) 0 (0%) 548 (37.2%) 132 (23.1%)
  No 1346 (60.0%) 0 (0%) 926 (62.8%) 420 (73.4%)
  Undefined 219 (9.8%) 199 (100%) 0 (0%) 20 (3.5%)
Symptoms
  Typical chest pain 490 (21.8%) 85 (42.7%) 399 (27.1%) 6 (1.1%)
  Atypical chest pain 608 (27.1%) 81 (40.7%) 505 (34.3%) 22 (3.9%)
  Non-specific symptoms 649 (28.9%) 33 (16.6%) 570 (38.7%) 46 (8.0%)
  None 498 (22.2%) 0 (0%) 0 (0%) 498 (87.1%)
Updated Diamond-Forrester score 36.4% ± 21.2% 51.1% ± 24.2% 38.6% ± 21.5% 25.9% ± 13.3%
Pre-test probability groups
  < 15% 370 (16.5%) 14 (7.0%) 213 (14.5%) 143 (25.0%)
  15–85% 1824 (81.2%) 165 (82.9%) 1230 (83.4%) 429 (75.0%)
  > 85% 51 (2.3%) 20 (10.1%) 31 (2.1%) 0 (0%)
Fig. 1  Histogram showing the 
distribution of CAD-scores 
in Non-CAD, Mild-CAD and 
Significant-CAD patients. The 
dashed line shows the propor-
tion of significant-CAD patients 
in each bin
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PLR were 0.27 and 1.52, respectively (Table 2). An increas-
ing CAD-score was associated with a higher risk of having 
CAD (Fig. 1).
The AUC of the cross-validation, testing for overfitting, was 
0.741, which is 0.009 lower than the AUC of the concluding 
CAD-score.
Comparison to the updated Diamond‑Forrester 
score
The AUC of the CAD-score was marginally superior to 
the updated Diamond-Forrester score; 0.750 versus 0.741 
(p = 0.64) when separating significant-CAD patients from 
Fig. 2  Reclassification results 
using the propose reclassifica-
tion scheme where patients with 
an intermediate PTP is reclassi-
fied to low probability in case of 
CAD-score ≤ 20
Pre-test probability 
>20
0 20 99
CAD-score
n=51n=1395n=227
n=472 n=923
High probability
n=51 (3.0%)
Intermediate probability
n=1395 (83.4%)
Low probability 
n=227 (13.6%)
Post-test probability 
High probability
n=51 (3.0%)
Intermediate probability
n= 923 (55.2%)
Low probability 
n=699 (41.8%)
≤20
Fig. 3  Receiving operating 
characteristics curve of the 
CAD-score and the updated 
Diamond-Forrester score
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other patients (Table 2). In patients referred for testing due 
to suspected CAD (patients from the AdoptCAD and the 
Dan-NICAD study) the AUC of the CAD-score was 0.749 
which was higher (p = 0.01) than the AUC of the updated 
Diamond-Forrester score 0.703 (p = 0.01). Similar in the 
Dan-NICAD study the CAD-score performed superior to 
the updated Diamond-Forrester score with AUCs of 0.720 
versus 0.661 (p = 0.01) respectively. In the AdoptCAD study 
alone the updated Diamond-Forrester score performed com-
parable to the CAD-score with AUCs of 0.776 versus 0.768 
(p = 0.79), respectively. The 15% PTP limit for the updated 
Diamond-Forrester score resulted in a sensitivity of 96.7% 
(93.3–98.7%) and a specificity of 17.9% (16.2–19.6%) 
(Table 2). Combining the CAD-score and the updated Dia-
mond-Forrester score using a linear discriminant function 
increased the AUC significantly to 0.774 (p = 0.013 versus 
the CAD-score and p = 0.0002 versus the updated Diamond 
Forrester score) in the complete database.
Correlation to disease level and diagnostic 
performance in sub‑groups
In patients undergoing CAG a weak correlation (r = 0.23, 
p < 0.0001) was found between the maximal stenosis degree 
and the CAD-score and a trend was seen towards an increase 
in CAD-score with increasing number of diseased vessels 
(r = 0.22, p < 0.0001) (Fig. 4). The CAD-score correlated 
with the logarithm of the CACS (r = 0.41, p < 0.0001). The 
negative predictive value was comparable between males 
and females, while the sensitivity of the CAD-score was 
Table 2  Diagnostic performance of the CAD-score and the updated Diamond-Forrester score (significant-CAD vs. other)
Negative predictive values, specificity, True Negative, False Negative and Likelihood ratio negative are calculated for CAD-scores ≤ 20 and 
updated Diamond-Forrester scores < 15%. Positive predictive values, sensitivity, True Positive, False Positive and Likelihood ratio positive are 
calculated for CAD-scores > 20 and updated Diamond-Forrester scores ≥ 15%
All AdoptCAD Dan-NICAD BIO-CAC 
CAD-score
  N: Other (Non-CAD and Mild-CAD) 2033 141 1321 571
  N: Significant-CAD 212 58 153 1
  Prevalence of CAD 9.4% 29.1% 10.4% 0.2%
  True negative 844 44 565 235
  False negative 24 1 23 0
  False positive 1189 97 756 336
  True positive 188 57 130 1
  AUC 0.750 (0.710–0.789) 0.768 (0.690–0.846) 0.720 (0.673–0.768) –
  Negative predictive value (p = 0.008) 97.2% (95.9–98.2%) 97.8% (88.2–99.9%) 96.1% (94.2–97.5%) –
  Positive predictive value (p < 0.001) 13.7% (11.9–15.6%) 37% (29.4–45.2%) 14.7% (12.4–17.2%) –
  Sensitivity (p = 0.02) 88.7% (83.6–92.6%) 98.3% (90.8–100%) 85% (78.3–90.2%) –
  Specificity (p = 0.03) 41.5% (39.4–43.7%) 31.2% (23.7–39.5%) 42.8% (40.1–45.5%) 41.2% (37.1–45.3%)
  Likelihood ratio positive 1.52 1.43 1.49 –
  Likelihood ratio negative 0.27 0.06 0.35 –
Updated Diamond-Forrester score
  N: Other (Non-CAD and Mild-CAD) 2033 141 1321 571
  N: Significant-CAD 212 58 153 1
  Prevalence of CAD 9.4% 29.1% 10.4% 0.2%
True negative 363 14 206 143
False negative 7 0 7 0
False positive 1670 127 1115 428
True positive 205 58 146 1
AUC 0.741 (0.702–0.781) 0.661 (0.612–0.71) –
  Negative predictive value (p = 0.072) 98.1% (96.1–99.2%) 100% (76.8–100%) 96.7% (93.3–98.7%) –
  Positive predictive value (p < 0.001) 10.9% (9.56–12.4%) 31.4% (24.7–38.6%) 11.6% (9.86–13.5%) –
  Sensitivity (p = 0.25) 96.7% (93.3–98.7%) 100% (93.8–100%) 95.4% (90.8–98.1%) –
  Specificity (p < 0.001) 17.9% (16.2–19.6%) 9.93% (5.54–16.1%) 15.6% (13.7–17.7%) 25% (21.5–28.8%)
Likelihood ratio positive 1.18 1.11 1.13 –
Likelihood ratio negative 0.18 0 0.29 –
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Table 3  Diagnostic performance of the CAD-scores in sub-groups
Negative predictive values (NPV) and specificity are calculated for CAD-scores ≤ 20. Positive predictive values (PPV) and sensitivity are calcu-
lated for CAD-scores > 20
*Only the Dan-NICAD included subjects with heart valve disease
n Prevalence AUC Sensitivity Specificity NPV PPV
Gender p < 0.0001 p = 0.36 p < 0.0001 p < 0.0001 p = 0.69 p < 0.0001
  Males 1060 13.9% 0.720 (0.671–
0.769)
94.6% (89.6–
97.6%)
27.3% (24.4–
30.3%)
96.9% (94.0–
98.6%)
17.3% (14.8–20.1%)
  Females 1185 5.5% 0.688 (0.615–
0.761)
75.4% (63.1–
85.2%)
53.1% (50.2–
56.1%)
97.4% (95.8–
98.5%)
8.54% (6.4–11.1%)
Diabetes p = 0.0001 p = 0.15 p = 0.26 p < 0.0001 p = 0.61 p = 0.0061
  Yes 118 19.5% 0.666 (0.535–
0.797)
95.7% (78.1–
99.9%)
22.1% (14.2–
31.8%)
95.5% (77.2–
99.9%)
22.9% (15.0–32.6%)
  No 2127 8.9% 0.753 (0.712–
0.794)
87.8% (82.3–
92.1%)
42.5% (40.3–
44.7%)
97.3% (95.9–
98.3%)
13% (11.2–14.9%)
Symptoms p < 0.0001 p = 0.0066 p = 0.012 p = 0.66 p = 0.076 p < 0.0001
  Typical chest pain 490 19.6% 0.795 (0.739–
0.851)
92.7% (85.6–
97.0%)
43.7% (38.7–
48.7%)
96.1% (92.1–
98.4%)
28.6% (23.7–34.0%)
  Atypical chest 
pain
608 9.9% 0.691 (0.614–
0.768)
78.3% (65.8–
87.9%)
41.2% (37.1–
45.5%)
94.6% (90.9–
97.1%)
12.7% (9.5–16.6%)
  Non-specific 
symptoms
649 8.5% 0.746 (0.669–
0.823)
92.7% (82.4–
98.0%)
40.9% (36.9–
45.0%)
98.4% (95.9–
99.6%)
12.7% (9.6–16.3%)
BMI p = 0.53 p = 0.013 p = 0.73 p < 0.0001 p = 0.66 p = 0.027
  < 20 70 10.0% 0.823 (0.628–1.00) 100% (59.0–100%) 58.7% (45.6–
71.0%)
100% (90.5–100%) 21.2% (9.0–38.9%)
   20 and < 25 724 10.6% 0.791 (0.729–
0.852)
89.6% (80.6–
95.4%)
49.5% (45.5–
53.4%)
97.6% (95.3–
98.9%)
17.4% (13.8–21.5%)
   25 and < 30 962 8.5% 0.706 (0.641–
0.771)
86.6% (77.3–
93.1%)
39.7% (36.4–
43.0%)
96.9% (94.6–
98.5%)
11.8% (9.3–14.6%)
   30 483 9.3% 0.750 (0.666–
0.835)
88.9% (75.9–
96.3%)
31.5% (27.2–
36.1%)
96.5% (92.0–
98.9%)
11.8% (8.5–15.7%)
Heart valve dis-
ease*
p = 0.81 p = 0.53 p = 0.37 p = 0.006 p = 0.56 p = 0.90
  Yes 58 10.3% 0.686 (0.440–
0.930)
100% (54.1–100%) 23.1% (12.5–
36.8%)
100% (73.5–100%) 13.0% (4.9–26.3%)
  No 2187 9.4% 0.750 (0.710–
0.790)
88.3% (83.2–
92.4%)
42.0% (39.8–
44.2%)
97.2% (95.9–
98.2%)
13.7% (11.9–15.6%)
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higher in males compared to females.(Table 3). The CAD-
score had similar sensitivity in all BMI groups, but there 
was a trend toward lower specificity with increasing BMI 
(Table 3). The sensitivity was highest in patients with typical 
chest pain and non-specific symptoms compared to atypical 
chest pain. Diabetes reduced the specificity of the CAD-
score (Table 3). Only the Dan-NICAD dataset included 
patients with pathological heart valve disease. In these 
patients, the sensitivity was increased to 100%, while the 
specificity was decreased to 23.1% (Table 3).
Discussion
Recent findings of low diagnostic yield at non-invasive test-
ing calls for a more rational approach to avoid unnecessary 
testing, providing both clinical and economic advantages. 
In this study we analysed the rule-out potential of a new 
CAD-score utilized before non-invasive testing of patients 
with suspected stable CAD. We found that the CAD-score 
enabled a significant and safe reclassification of patients, 
which could reduce the need for more expensive testing in 
patients presenting with chest pain.
The CADScor®System as a rule‑out device
According to the current ESC guideline patients with inter-
mediate PTP (15–85%) should undergo non-invasive testing 
[1]. In patients referred for testing due a suspicion of CAD 
we reclassified patients from the intermediate PTP group 
into the low probability group for negative CAD-scores. 
Thereby 699 (41.8%) patients could potentially avoid fur-
ther costly testing, which is more than three times as many 
as if only the Diamond-Forrester score was used for rule-out 
(227 patients, 13.6%). Of notice, the 2016 NICE guidelines 
mention the CAD-score as a potential clinically relevant pre-
diction model [33]. The proposed procedure was associated 
with a minor and insignificant increase in the proportion of 
significant-CAD patients in the low probability group from 
3.1% to 4.0%.
A positive CAD-score ( > 20) resulted in a sensitivity of 
88.7% which in the present low prevalence population (9.4% 
CAD) leads to a NPV at 97.2%. Thereby the probability of 
having significant-CAD was 2.8% for patients with a negative 
CAD-score ( ≤ 20). This probability is much lower than the 
15% PTP threshold defined by the ESC guidelines for stable 
CAD that states that it is safe to assume that patients with a 
PTP below 15% have no significant CAD and no further test-
ing is recommended. This suggests that the CAD-score safely 
rules-out CAD in the low and intermediate PTP population. 
The proposed use of the CADScor®System is as a first-line 
test before other non-invasive testing. This is reflected in the 
Dan-NICAD population which had an average PTP at 38.6%, 
where the CAD-score had a significantly higher AUC than the 
Diamond-Forrester score.
The CAD‑score in sub‑groups
Investigating the effect of risk factors potentially interfering 
with the CAD-score result, such as high BMI, diabetes or heart 
valve disease resulted in similar or increased sensitivity of the 
CAD-score in sub-group analyses, and in lower specificity, 
see Table 3. This indicates that the rule-out efficacy is lower in 
these sub-groups, but the rule-out safety is the same as in the 
remaining population. As in other risk models including gen-
der, the sensitivity was lower in females compared to males. 
Despite this, the CAD-score had comparable rule-out safety 
in males and females, with similar negative predictive values.
Study limitations
The current study is a retrospective analysis of pooled data 
from existing cohorts and might therefore not capture all 
aspects of the clinical workflow. The database included a 
group of asymptomatic subjects from a screening study and 
it included a group of patients referred for CAG. Neither of 
these subjects are typical representatives for patients referred 
for non-invasive testing. However, the baseline character-
istics such as age, gender and PTP of the pooled data cor-
responded well to the characteristics of the Dan-NICAD 
study which included only patients referred for non-invasive 
testing. The conclusion of the current study is limited to 
low to intermedia risk patients since the number of high-
risk patients (updated Diamond Forrester score > 85%) was 
very low in the current study. The CAD-score algorithm 
described in the current paper is finetuned in the complete 
database before implementation in the CAD-score device. 
This induces the risk of overfitting the algorithm to the data, 
however the cross-validation of the algorithm showed only 
a small decrease in AUC of 0.009 thereby the degree of 
overfitting can be considered unimportant for the overall 
results. As recommended in the current ESC guidelines, the 
updates Diamond-Forrester score was used for PTP estima-
tion. Other risk assessment models like the CAD-consortium 
scores [34] or PROMISE Minimal-Risk Tool [35] estimate 
lower risk levels which might alter interaction between PTP 
and the CAD-score. To further understand the interaction 
between long term in risk and CAD-scores future studies 
should include long term follow up data.
Conclusion
In the current study, we simulated use of the CAD-score to 
rule-out CAD in patients with intermediate PTP and sug-
gest that the method potentially can reduce the number of 
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patients who should be referred for non-invasive testing, 
without a significant increase in the false negative rate. If 
these finding can be replicated in prospective studies, the 
use of the CAD-score could significantly alter the current 
practise of early rule-out of stable CAD providing important 
clinical and economic advantages.
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